Rohto, JP3982400008

Rohto stock: Q2 recurring profit falls 11.2%

Published on 11/18/2026 at 02:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Rohto stock faces a weaker first half as recurring profit declines. Revenue still rises, while the full-year forecast remains unchanged.

Rohto reports a mixed first half

  • Revenue increased in the April-to-September period, while recurring profit and net income declined.
  • Rohto kept its full-year forecast unchanged after the interim results.
  • The second-quarter slowdown put pressure on recurring profit and the operating margin.
Rohto, JP3982400008, Illustration mit AI erstellt.

Rohto Pharmaceutical reported on November 12 that recurring profit fell in the first half of fiscal 2027, even as revenue increased. The results were published after the Tokyo market close and covered the April-to-September period.

Kabutan reported that consolidated recurring profit declined 11.2% year over year to 21.845 billion yen. Revenue rose 9.0% to 179.006 billion yen, while operating profit increased 8.5% to 20.953 billion yen.

Second-quarter pressure increased

The July-to-September quarter was weaker than the first-half total. Recurring profit fell 13.3% year over year to 7.354 billion yen, while operating profit declined 4.3% to 7.290 billion yen. The operating margin narrowed to 8.3% from 9.3% a year earlier.

Net income attributable to shareholders decreased 6.5% in the first half to 16.498 billion yen. The result represented 46.1% of the full-year recurring-profit plan, below the five-year average progress rate cited in the report.

Full-year outlook stays unchanged

Rohto retained its fiscal-year forecast for revenue of 372.3 billion yen, operating profit of 45.0 billion yen and recurring profit of 47.4 billion yen. The company also maintained its forecast for net income of 35.2 billion yen.

The unchanged outlook leaves the second half carrying a larger share of the annual plan. Kabutan's figures imply that Rohto expects recurring profit to grow in the October-to-March period compared with the same period a year earlier.

Rohto's healthcare portfolio

Rohto Pharmaceutical develops and sells healthcare, eye-care and skincare products, with its business centered in Japan and international markets. Its portfolio spans consumer health and beauty-related products.

In the Japanese consumer-health market, Rohto competes with larger diversified groups such as Kao and Shiseido in skincare, while Santen Pharmaceutical has a more specialized focus on ophthalmic products.

The Nikkei 225 provides the relevant Japanese market context for Rohto's home market: Current Nikkei 225 market environment.

More news and analyses on Rohto stock are available here.

Rohto Pharmaceutical at a glance

  • Company: ROHTO Pharmaceutical Co., Ltd.
  • ISIN: JP3982400008
  • Tokyo ticker: 4527
  • Reporting period: April to September 2026
  • Fiscal year: Year ending March 2027
Disclaimer...
en | JP3982400008 | ROHTO | boerse | 70529079 | bgmi